Recurrent glioblastoma
Conditions
Interventions
NovoTTF-100A is composed with transducer array sheets, leads and a connection box.Transducer array sheets should be attached on frontal, occipital and bilateral temporal regions of the patients.The ma
s consent.
Sponsors
Osaka Medical College, Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who agreed to participate in this clinincal study in writing after receiving sufficient explanation. 2) Patients with definitive progression of GB on MR, CT or PET scans. 3)The patient should be diagnosed as GB by histology. 4) The patient should be treated by stndard of care such as radiation, chemotherapy with TMZ and/or bevacizumab. 4) KPS is 30% or more. 5) Patients who demonstrate appropriate bone marrow, hepatic and renal functions in laboratory tests within four weeks before the registration. a) neutrophil count more than 1,500 /mm3 b) Hemoglobin level more than 10.0 g/dL c) Platelet count more than 10.0 x 104 /micro L d) Serum creatine level less than 1.4 mg/dL e) ALT levels less than 100 IU/L f) AST levels less than 100 IU/L g) Total birirubin less than1.5 mg/dL
Exclusion criteria
Exclusion criteria: 1) Patients with the infra-tentorial lesions. 2) Patients received with pacemakers or shuntting devices with magnet actions. 3) Pateients with sever systemic complications, necessary for hospitalization. 4) Patients with unhealed scalp wound. 5) Patients with infectious diseses,necessary for antibiotics, so on. 6) Female patients in definitive or possible pregnancy or in breast-feeding. 7) Other patients whose participation in the present study is considered inappropriate by a Principal Investigator or Clinical Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor response Adverse effects | — |
Countries
Japan
Contacts
Public ContactShin-Ichi Miyatake
Osaka Medical College Cancer Center
Outcome results
None listed